Biologics

The Louis V. Gerstner Jr. Fund at Vanguard Charitable gave Rochester, Minn.-based Mayo Clinic a $10 million grant.

Heraeus Medical launched the Palacos R & R+G pro All-in-One Fixation System for the U.S. market.

Artoss is an orthobiologics company.

InVivo Therapeutics entered into a joint research agreement with Q Therapeutics to evaluate the safety and feasibility of combining InVivo's Neuro-Spinal Scaffold with stem cells.

Bioventus received approval to market Durolane for hip and knee osteoarthritis in Brazil and selected Pfizer as its exclusive distribution partner.

Bone Solutions Inc. announced first 250 cases of its magnesium-based bone void filler OsteoCrete were implanted.

Maryland Technology Development Corp., awarded the first two grants from the state's Stem Cell Research Fund, Baltimore Business Journal reports.

The global orthobiologics market is projected to grow at a 3.5 percent compound annual growth rate, topping $6.5 billion by 2027, according to a Future Market Insights report.

Orthobiologics company Kuros Biosciences named its strategic advisory board.

Reinvent Biologics appointed orthopedic surgeon David Drez Jr., MD, as CMO.